

16 POUŽITÁ LITERATURA A DOPORUČENÉ ZDROJE

- Peeters, A. et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. *Annals of Internal Medicine*. 2003, 138(1), 24–32.
- Walls, H. L. et al. Obesity and trends in life expectancy. In: *Journal of obesity* [online]. 2012 [cit. 2021-01-07]. Dostupné z: doi:10.1155/2012/107989
- Pirie, K. et al. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. *Lancet (London, England)*. 2013, 381(9861), 133–141.
- Jura, M. a Kozak, L. P. Obesity and related consequences to ageing. *Age (Dordrecht, Netherlands)*. 2016, 38(1), 23.
- Global BMI Mortality Collaboration et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *Lancet*. 2016, 388(10046), 776–786.
- Zákon č. 110/1997 Sb., o potravinách a tabákových výrobcích a o změně a doplnění některých souvisejících zákonů. In: *Sbírka zákonů*. 24. 4. 1997. ISSN 1211-1244.
- Mukherjee, S., Dudley, J. I. a Das, D. K. Dose-dependency of resveratrol in providing health benefits. *Dose Response*. 2010, 8(4), 478–500.
- Li, Y. R., Li, S. a Lin, C. C. Effect of resveratrol and pterostilbene on aging and longevity. *Biofactors*. 2018, 44(1), 69–82.
- Stojanović, S., Sprinz, H. a Brede, O. Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. *Archives of Biochemistry and Biophysics*. 2001, 391(1), 79–89.
- Aggarwal, B. B. et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. *Anticancer Research*. 2004, 24(5A), 2783–2840.
- Alberdi, G. et al. Changes in white adipose tissue metabolism induced by resveratrol in rats. *Nutrition & Metabolism (London)*. 2011, 8(1), 29.
- Tomé-Carneiro, J. et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. *The American Journal of Cardiology*. 2012, 110(3), 356–363.
- Marambaud, P., Zhao, H. a Davies, P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. *Journal of Biological Chemistry*. 2005, 280(45), 37377–37382.
- Manach, C. et al. Polyphenols: food sources and bioavailability. *The American Journal of Clinical Nutrition*. 2004, 79(5), 727–747.
- Mlcek, J. et al. Quercetin and Its Anti-Allergic Immune Response. In: *Molecules* [online]. 2016, 21(5). [cit. 2020-10-10]. Dostupné z: doi:10.3390/molecules21050623
- Jeong, J. H. et al. Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression. *Journal of cellular biochemistry*. 2009, 106(1), 73–82.
- Gibellini, L. et al. Quercetin and Cancer Chemoprevention. In: *Evidence-Based Complementary and Alternative Medicine* [online]. 2011. [cit. 2020-12-10]. Dostupné z: doi:10.1093/ecam/nea053
- Brito, A. F. et al. Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics? *Current Medicinal Chemistry*. 2015, 22(26), 3025–3039.
- Tang, S. M. et al. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. In: *Biomedicine & Pharmacotherapy* [online]. 2020, 121. [cit. 2021-01-18]. Dostupné z: doi:10.1016/j.biopha.2019.109604
- Graefe, E. U. et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. *The Journal of Clinical Pharmacology*. 2001, 41(5), 492–499.
- Terao, J. Factors modulating bioavailability of quercetin-related flavonoids and the consequences of their vascular function. In: *Biochemical Pharmacology* [online]. 2017, 139, 15–23 [cit. 2021-03-17]. Dostupné z: doi:10.1016/j.bcp.2017.03.021
- Li, Y. et al. Quercetin, Inflammation and Immunity. *Nutrients*. 2016, 8(3), 167.
- National Center for Biotechnology Information. Quercetin. In: *PubChem* [online]. 2021 [cit. 2021-03-28]. Dostupné z: <https://pubchem.ncbi.nlm.nih.gov/compound/Quercetin>
- Jin, F. et al. The variable plasma quercetin response to 12-week quercetin supplementation in humans. *European Journal of Clinical Nutrition*. 2010, 64(7), 692–697.
- Knab, A. M. et al. Influence of quercetin supplementation on disease risk factors in community-dwelling adults. *Journal of the American Dietetic Association*. 2011, 111(4), 542–549.
- Khoo, H. E. et al. Anthocyanidins and anthocyanins: colored pigments as food, pharmaceutical ingredients, and the potential health benefits. *Food & Nutrition Research*. 2017, 61(1).
- Khoo, H. E. et al. Nutrients for Prevention of Macular Degeneration and Eye-Related Diseases. *Antioxidants (Basel)*. 2019, 8(4), 85.
- Fairlie-Jones, L. et al. The Effect of Anthocyanin-Rich Foods or Extracts on Vascular Function in Adults: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. *Nutrients*. 2017, 9(8).
- Basu, A., Rhone, M. a Lyons T. J. Berries: emerging impact on cardiovascular health. *Nutrition Reviews*. 2010, 68(3), 168–177.
- He, J. a Giusti, M. M. Anthocyanins: natural colorants with health-promoting properties. *Annual Review of Food Science and Technology*. 2010, 1, 163–187.
- Mattioli, R. et al. Anthocyanins: A Comprehensive Review of Their Chemical Properties and Health Effects on Cardiovascular and Neurodegenerative Diseases. *Molecules (Basel, Switzerland)*. 2020, 25(17), 3809.
- Mink, P. J. et al. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. *The American Journal of Clinical Nutrition*. 2007, 85(3), 895–909.
- Guo, H. a Ling, W. The update of anthocyanins on obesity and type 2 diabetes: experimental evidence and clinical perspectives. *Reviews in Endocrine and Metabolic Disorders*. 2015, 16(1), 1–13.
- Turrini, E., Ferruzzi, L. a Fimognari, C. Possible Effects of Dietary Anthocyanins on Diabetes and Insulin Resistance. *Current Drug Targets*. 2017, 18(6), 629–640.
- Wang, L. S. a Stoner, G. D. Anthocyanins and their role in cancer prevention. *Cancer Letters*. 2008, 269(2), 281–290.
- Luo, W. P. et al. High consumption of vegetable and fruit colour groups is inversely associated with the risk of colorectal cancer: a case-control study. *British Journal of Nutrition*. 2015, 113(7), 1129–1138.
- De Pascual-Teresa, S. a Sanchez-Ballesta, M. T. Anthocyanins: from plant to health. *Phytochemistry Reviews*. 2008, 7, 281–299.
- Lin, B. W. et al. Effects of anthocyanins on the prevention and treatment of cancer. In: *British Journal of Pharmacology* [online]. 2017, 174(11), 1226–1243 [cit. 2021-02-20]. Dostupné z: doi:10.1111/bph.13627
- Dharmawansa, K., Hoskin, D. W. a Rupasinghe, H. Chemopreventive Effect of Dietary Anthocyanins against Gastrointestinal Cancers: A Review of Recent Advances and Perspectives. *International Journal of Molecular Sciences*. 2020, 21(18), 6555.
- Kent, K. et al. Food-based anthocyanin intake and cognitive outcomes in human intervention trials: a systematic review. *Journal of Human Nutrition and Dietetics*. 2017, 30(3), 260–274.
- Yang, L. et al. Effects of Anthocyanins on Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Advances in Nutrition*. 2017, 8(5), 684–693.
- Vendrame, S. a Klimis-Zacas, D. Potential Factors Influencing the Effects of Anthocyanins on Blood Pressure Regulation in Humans: A Review. *Nutrients*. 2019, 11(6), 1431.
- Bendokas, V. et al. Anthocyanins: From the Field to the Antioxidants in the Body. *Antioxidants (Basel, Switzerland)*. 2020, 9(9), 819.
- Silva, H. R. D. et al. *Euterpe oleracea* Mart. (aai): an old known plant with a new perspective. In: *African Journal of Pharmacy and Pharmacology* [online]. 2016, 10(46). [cit. 2021-03-16]. Dostupné z: doi:10.5897/AJPP2016.4686
- Silva, D. F. et al. Açaí (*Euterpe oleracea* Mart) Consumption and Prevention of Chronic Diseases: Is There an Association? A Preliminary Study. In: *ScientificWorldJournal* [online]. 2020 [cit. 2020-10-15]. Dostupné z: doi:10.1155/2020/5782485
- Silva Leitão Peres, N. et al. Medicinal effects of Peruvian maca (*Lepidium meyenii*): a review. *Food & Function*. 2020, 11(1), 83–92.
- Xie, C. et al. The açai flavonoid velutin is a potent anti-inflammatory agent: blockade of LPS-mediated TNF- α and IL-6 production through inhibiting NF- κ B activation and MAPK pathway. *Journal of Nutritional Biochemistry*. 2012, 23(9), 1184–1191.
- Zhao, L. et al. Neuroprotective, anti-amyloidogenic and neurotrophic effects of apigenin in an Alzheimer's disease mouse model. *Molecules*. 2013, 18(8), 9949–9965.
- Patil, S. P. et al. Neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice. *Neuropharmacology*. 2014, 86, 192–202.
- Yamagata, K. et al. Stroke status evoked adhesion molecule genetic alterations in astrocytes isolated from stroke-prone spontaneously hypertensive rats and the apigenin inhibition of their expression. In: *Stroke Research and Treatment* [online]. 2010 [cit. 2020-10-10]. Dostupné z: doi:10.4061/2010/386389
- Cai, M. et al. Apigenin-7-O- β -D-(6"-p-coumaroyl)-Glucopyranoside Treatment Elicits Neuroprotective Effect against Experimental Ischemic Stroke. *International Journal of Biological Sciences*. 2016, 12(1), 42–52.

52. Domínguez Avila, J. A. et al. The antidiabetic mechanisms of polyphenols related to increased glucagon-like peptide-1(GLP1) and Insulin signaling. In: *Molecules* [online]. 2017, 22(6). [cit. 2021-01-09]. Dostupné z: doi:10.3390/molecules22060903
53. Qin, Y. et al. Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects. *The American Journal of Clinical Nutrition*. 2009, 90(3), 485–492.
54. Udani, J. K. et al. Effects of Açai (*Euterpe oleracea* Mart.) berry preparation on metabolic parameters in a healthy overweight population: a pilot study. *Nutrition Journal*. 2011, 12, 45.
55. Feio, C. A. et al. *Euterpe oleracea* (açai) modifies sterol metabolism and attenuates experimentally-induced atherosclerosis. *Journal of Atherosclerosis and Thrombosis*. 2012, 19(3), 237–245.
56. De Souza, M. O. et al. The hypocholesterolemic activity of açai (*Euterpe oleracea* Mart.) is mediated by the enhanced expression of the ATP-binding cassette, subfamily G transporters 5 and 8 and low-density lipoprotein receptor genes in the rat. *Nutrition Research*. 2012, 32(12), 976–984.
57. De Moura, R. S. a Resende, Â. C. Cardiovascular and metabolic effects of Açai, an amazon plant. *Journal of Cardiovascular Pharmacology*. 2016, 68(1), 19–26.
58. Braun, L. a Cohen, M. *Herbs & natural supplements: An evidence-based guide. Vol. 2, 4th ed. Elsevier Health Sciences, 2014. ISBN 9780729581738.*
59. Melchart, D. et al. Immunomodulation with *Echinacea* – a systematic review of controlled clinical trials. *Phytomedicine*. 1994, 1(3), 245–254.
60. Kim, H. R. et al. Immune enhancing effects of *Echinacea purpurea* root extract by reducing regulatory T cell number and function. *Natural Product Communications*. 2014, 9(4), 511–514.
61. Zhai, Z. et al. Enhancement of innate and adaptive immune functions by multiple *Echinacea* species. *Journal of Medicinal Food*. 2007, 10(3), 423–434.
62. Chiou, S. Y. et al. Antioxidant, Antidiabetic, and Antihypertensive Properties of *Echinacea purpurea* Flower Extract and Caffeic Acid Derivatives Using *In Vitro* Models. *Journal of Medicinal Food*. 2017, 20(2), 171–179.
63. Yotsawimonwat, S. et al. Skin improvement and stability of *Echinacea purpurea* dermatological formulations. *International Journal of Cosmetic Science*. 2010, 32(5), 340–346.
64. Oláh, A. et al. *Echinacea purpurea*-derived alkylamides exhibit potent anti-inflammatory effects and alleviate clinical symptoms of atopic eczema. *Journal of Dermatological Science*. 2017, 88(1), 67–77.
65. Sharma, M. et al. The potential use of *Echinacea* in acne: control of *Propionibacterium* acnes growth and inflammation. *Phytotherapy Research*. 2011, 25(4), 517–521.
66. Haller, J., Hohmann, J. a Freund, T. F. The effect of *Echinacea* preparations in three laboratory tests of anxiety: comparison with chlordiazepoxide. *Phytotherapy Research*. 2010, 24(11), 1605–1613.
67. Haller, J. et al. The Anxiolytic Potential and Psychotropic Side Effects of an *Echinacea* Preparation in Laboratory Animals and Healthy Volunteers. *Phytotherapy Research*. 2013, 27(1), 54–61.
68. Huang, D. F. et al. Effect of phenylethanoid glycosides and polysaccharides from the seed of *Plantago asiatica* L. on the maturation of murine bone marrow-derived dendritic cells. *European Journal of Pharmacology*. 2009, 620(1–3), 105–111.
69. Chu P. H. et al. Effect of *Lycium Barbarum* (Wolfberry) Polysaccharides on Preserving Retinal Function after Partial Optic Nerve Transection. In: *PLoS One* [online]. 2013. [cit. 2021-02-22]. Dostupné z: doi:10.1371/journal.pone.0081339
70. Liu, W. et al. Structure characterization, chemical and enzymatic degradation, and chain conformation of an acidic polysaccharide from *Lycium barbarum* L. *Carbohydrate Polymers*. 2016, 147, 114–124.
71. Xie, J. H. et al. Recent advances in bioactive polysaccharides from *Lycium barbarum* L., *Zizyphus jujuba* Mill, *Plantago* spp., and *Morus* spp.: structures and functionalities. *Food Hydrocolloids*. 2016, 60, 148–160.
72. Xu, X. et al. Anti-diabetic properties of *Momordica charantia* L. polysaccharide in alloxan-induced diabetic mice. *International Journal of Biological Macromolecules*. 2015, 81, 538–543.
73. Amagase, H. a Nance, D. M. A randomized, double-blind, placebo-controlled, clinical study of the general effects of a standardized *Lycium barbarum* (Goji) Juice, GoChi. *Journal of Alternative and Complementary Medicine*. 2008, 14(4), 403–412.
74. Jin, M. et al. Biological activities and potential health benefit effects of polysaccharides isolated from *Lycium barbarum* L. *International Journal of Biological Macromolecules*. 2013, 54, 16–23.
75. Ma, Z. F. et al. Goji berries as a potential natural antioxidant medicine: An insight into their molecular mechanisms of action. *Oxidative Medicine and Cellular Longevity*. 2019.
76. Bensky, D. *Chinese Herbal Medicine: Materia Medica*. 3rd ed., Eastland Press, 2004. ISBN 978-0939616824.
77. Bucheli, P. et al. Biomolecular and Clinical Aspects of Chinese Wolfberry. In: *Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects* [online]. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis, 2011. Chapter 14. Dostupné z: <https://www.ncbi.nlm.nih.gov/books/NBK92756/>
78. Navrátilová, L. Goji – obsahové látky a léčivé účinky. *Praktické lékařství*. 2016, 12(3), 108–110.
79. Lal, B. et al. Efficacy of curcumin in the management of chronic anterior uveitis. *Phytotherapy Research*. 1999, 13(4), 318–322.

80. Jurenka, J. S. Anti-inflammatory properties of curcumin, a major constituent of *Curcuma longa*: a review of preclinical and clinical research. *Alternative Medicine Review*. 2009, 14(2), 141–153.
81. Takada, Y. et al. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. *Oncogene*. 2004, 23(57), 9247–9258.
82. Song, E. K. et al. Diarylheptanoids with free radical scavenging and hepatoprotective activity *in vitro* from *Curcuma longa*. In: *Planta Medica* [online]. 2001, 67(9), 876–877 [cit. 2020-10-13]. Dostupné z: doi:10.1055/s-2001-18860
83. Kumar, G. S. et al. Free and bound phenolic antioxidants in amla (*Emblica officinalis*) and turmeric (*Curcuma longa*): *Journal of Food Composition and Analysis*. 2006, 19(5), 446–452.
84. Belcaro, G. et al. Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. *Pain Medicine*. 2010, 52(2 Suppl 1), 55–62.
85. Chandran, B. a Goel, A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. *Phytotherapy Research*. 2012, 26(11), 1719–1725.
86. Henrotin, Y., Priem, F. a Mobasher, A. Curcumin: A new paradigm and therapeutic opportunity for the treatment of osteoarthritis: Curcumin for osteoarthritis management. In: *SpringerPlus* [online]. 2013, 2(1). [cit. 2020-10-19]. Dostupné z: doi:10.1186/2193-1801-2-56
87. Belcaro, G. et al. A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment. *Phytotherapy Research*. 2014, 28(3), 444–450.
88. Chuengsamarn, S. et al. Curcumin extract for prevention of type 2 diabetes. *Diabetes Care*. 2012, 35(11), 2121–2127.
89. Na, L. X. et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: A double-blind, placebo-controlled trial. *Molecular Nutrition & Food Research*. 2013, 57(9), 1569–1577.
90. Hlavačková, L. et al. Spice up the hypertension diet—Curcumin and piperine prevent remodeling of aorta in experimental L-NAME induced hypertension. *Nutrition & Metabolism*. 2011, 8.
91. Sahebkar, A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. *Phytotherapy Research*. 2013, 28(5), 633–642.
92. Bradford, P. G. Curcumin and obesity. *BioFactors*. 2013, 39(1), 78–87.
93. Singh, S. a Aggarwal, B. B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. *Journal of Biological Chemistry*. 1995, 270(42), 24995–25000.
94. Shoba, G. et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Medica*. 1998, 64(4), 353–356.
95. Krinsky, N. I., Landrum, J. T. a Bone, R. A. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. *Annual Review of Nutrition*. 2003, 23, 171–201.
96. Castenmiller, J. J. et al. The food matrix of spinach is a limiting factor in determining the bioavailability of beta-carotene and to a lesser extent of lutein in humans. *Journal of Nutrition*. 1999, 129(2), 349–355.
97. Seddon, J. M. et al. *Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA*. 1994, 272(18), 1413–1420.
98. Huang, Y. M. et al. Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. In: *BioMed Research International* [online]. 2015 [cit. 2021-03-15]. Dostupné z: doi:10.1155/2015/564738
99. Kostic, D., White, W. S. a Olson, J. A. Intestinal absorption, serum clearance, and interactions between lutein and beta-carotene when administered to human adults in separate or combined oral doses. *The American Journal of Clinical Nutrition*. 1995, 62(3), 604–610.
100. Van den Berg, H. a van Vliet, T. Effect of simultaneous, single oral doses of beta-carotene with lutein or lycopene on the beta-carotene and retinyl ester responses in the triacylglycerol-rich lipoprotein fraction of men. *The American Journal of Clinical Nutrition*. 1998, 68(1), 82–89.
101. Thurmann, P. A. et al. Plasma kinetics of lutein, zeaxanthin, and 3-dehydro-lutein after multiple oral doses of a lutein supplement. *The American Journal of Clinical Nutrition*. 2005, 82(1), 88–97.
102. Ma, L. et al. A dose-response meta-analysis of dietary lutein and zeaxanthin intake in relation to risk of age-related cataract. *Graefes Archive for Clinical and Experimental Ophthalmology*. 2014, 252(1), 63–70.
103. Shao, A. a Hathcock, J. N. Risk assessment for the carotenoids lutein and lycopene. *Regulatory Toxicology and Pharmacology*. 2006, 45(3), 289–298.
104. Omar, H. R. et al. Licorice abuse: time to send a warning message. *Therapeutic Advances in Endocrinology and Metabolism*. 2012, 3(4), 125–138.
105. Deutch, M. R. et al. Bioactive Candy: Effects of Licorice on the Cardiovascular System. *Foods (Basel, Switzerland)*. 2019, 8(10).
106. Wang, L. et al. The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. *Acta Pharmaceutica Sinica B*. 2015, 5(4), 310–315.
107. Mills, S. a Bone, K. *The Essential Guide to Herbal Safety*. 1st ed. Elsevier: Churchill Livingstone, 2005. ISBN 9780443071713.

108. Tůmová, L. Lékořice – terapeutické účinky a možné interakce. *Praktické lékárenství*. 2011, 7(6), 286–287.
109. Drake, C. L., Roehrs, T. a Roth, T. Insomnia causes, consequences, and therapeutics: an overview. *Depress Anxiety*. 2003, 18(4), 163–176.
110. Bhaskar, S., Hemavathy, D. a Prasad, S. Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities. *Journal of Family Medicine and Primary Care*. 2016, 5(4), 780–784.
111. Mahady, G. B. et al. Ginsengs: A Review of Safety and Efficacy. *Nutrition in Clinical Care*. 2001, 3(2), 90–101.
112. Burrowes, J. D. a Van Houten, G. Herbs and dietary supplement use in patients with stage 5 chronic kidney disease. *Nephrology Nursing Journal*. 2006, 33(1), 85–88.
113. Bucci, L. R. Selected herbals and human exercise performance. *The American Journal of Clinical Nutrition*. 2000, 72(2 Suppl), 624S–636S.
114. Hong, Y. J. et al. Korean red ginseng (*Panax ginseng*) ameliorates type 1 diabetes and restores immune cell compartments. *Journal of Ethnopharmacology*. 2012, 144(2), 225–233.
115. Attele, A. S., Wu, J. A. a Yuan, C. S. Ginseng pharmacology: multiple constituents and multiple actions. *Biochemical Pharmacology*. 1999, 58(11), 1685–1693.
116. Park, E. K. et al. Ginsenoside Rh1 Possesses Antiallergic and Anti-Inflammatory Activities. *International Archives of Allergy and Immunology*. 2004, 133(2), 113–120.
117. Li, N. et al. Protective effects of ginsenoside Rg₂ against glutamate-induced neurotoxicity in PC12 cells. *Journal of Ethnopharmacology*. 2007, 111(3), 458–463.
118. Xiang, Y. Z. et al. A comparison of the ancient use of ginseng in traditional chinese medicine with modern pharmacological experiments and clinical trials. *Phytotherapy Research*. 2008, 22(7), 851–858.
119. Kim, H. J., Kim, P. a Shin, C. Y. A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. *Journal of Ginseng Research*. 2013, 37(1), 8–29.
120. Kim, J. H. et al. Role of ginsenosides, the main active components of *Panax ginseng*, in inflammatory responses and diseases. *Journal of Ginseng Research*. 2017, 41(4), 435–443.
121. Darbinyan, V. et al. Clinical trial of *Rhodiola rosea* L. extract SHR-5 in the treatment of mild to moderate depression. *Nordic Journal of Psychiatry*. 2007, 61(5), 343–348.
122. Perfumi, M. a Mattioli, L. Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% salidroside *Rhodiola rosea* L. extract in mice. *Phytotherapy Research*. 2007, 21(1), 37–43.
123. Panossian, A., Wikman, G. a Sarris, J. Rosenroot (*Rhodiola rosea*): traditional use, chemical composition, pharmacology and clinical efficacy. *Phytotherapy Research*. 2010, 24(7), 481–493.
124. Ishaque, S. et al. *Rhodiola rosea* for physical and mental fatigue: a systematic review. *BMC Complementary Medicine and Therapies*. 2012, 12, 12.
125. Kosanovic, D. et al. *Rhodiola*: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review. *Pulmonary Circulation*. 2013, 3(3), 499–506.
126. Radomska-Leśniewska, D. M. et al. Angiomodulatory properties of *Rhodiola* spp. and other natural antioxidants. *Central European Journal of Immunology*. 2015, 40(2), 249–262.
127. Amsterdam, J. D. a Panossian, A. G. *Rhodiola rosea* L. as a putative botanical antidepressant. *Phytotherapy Research*. 2016, 30(7), 770–783.
128. Khanna, K. et al. Golden root: A wholesome treat of immunity. *Biomedicine & Pharmacotherapy*. 2017, 87, 496–502.
129. Noreen, E. E. et al. The effects of an acute dose of *Rhodiola rosea* on endurance exercise performance. *The Journal of Strength and Conditioning Research*. 2013, 27(3), 839–847.
130. Duncan, M. J. a Clarke, N. D. The Effect of Acute *Rhodiola rosea* Ingestion on Exercise Heart Rate, Substrate Utilisation, Mood State, and Perceptions of Exertion, Arousal, and Pleasure/Displeasure in Active Men. In: *Journal of Sports Medicine (Hindawi Publishing Corporation)* [online]. 2014 [cit. 2021-02-24]. Dostupné z: doi:10.1155/2014/563043
131. De Bock, K. et al. Acute *Rhodiola rosea* intake can improve endurance exercise performance. *International Journal of Sport Nutrition and Exercise Metabolism*. 2004, 14(3), 298–307.
132. Walker, T. B. et al. Failure of *Rhodiola rosea* to alter skeletal muscle phosphate kinetics in trained men. *Metabolism*. 2007, 56(8), 1111–1117.
133. Tu, Y. et al. *Rhodiola crenulata* induces death and inhibits growth of breast cancer cell lines. *Journal of Medicinal Food*. 2008, 11(3), 413–423.
134. Liu, Z. et al. *Rhodiola rosea* extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy. *Molecular Carcinogenesis*. 2012, 51(3), 257–267.
135. Fan, X. J. et al. Salidroside induces apoptosis and autophagy in human colorectal cancer cells through inhibition of PI3K/Akt/mTOR pathway. *Oncology Reports*. 2016, 36(6), 3559–3567.
136. Kelly, G. S. *Rhodiola rosea*: a possible plant adaptogen. *Alternative Medicine Review*. 2001, 6(3), 293–302.
137. Olsson, E. M., von Schéele, B., Panossian, A. G. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract shr-5 of the roots of *Rhodiola rosea* in the treatment of subjects with stress-related fatigue. *Planta Medica*. 2008, 75(2), 105–112.

138. Edwards, D., Heufelder, A. a Zimmermann, A. Therapeutic effects and safety of *Rhodiola rosea* extract WS® 1375 in subjects with life-stress symptoms--results of an open-label study. *Phytotherapy Research*. 2012, 26(8), 1220–5.
139. Mao, J. J. et al. *Rhodiola rosea* versus sertraline for major depressive disorder: A randomized placebo-controlled trial. *Phytotherapy Research*. 2015, 29(3), 394–399.
140. Panossian, A. a Wikman, G. Pharmacology of *Schisandra chinensis* Bail.: an overview of Russian research and uses in medicine. *Journal of Ethnopharmacology*. 2008, 118(2), 183–212.
141. Zhang, M. et al. The influence of Schisandrin B on a model of Alzheimer's disease using β -amyloid protein A β_{1-42} -mediated damage in SH-SY5Y neuronal cell line and underlying mechanisms. *Journal of Toxicology and Environmental Health, Part A*. 2017, 80(22), 1199–1205.
142. Srichana, D., Taengtip, R. a Kondo, S. Antimicrobial activity of *Gynostemma pentaphyllum* extracts against fungi-producing aflatoxin and fumonisin and bacteria causing diarrheal disease. *The Southeast Asian Journal of Tropical Medicine and Public Health*. 2011, 42(3), 704–710.
143. Muller, C. et al. Prevention of free fatty acid-induced lipid accumulation, oxidative stress, and cell death in primary hepatocyte cultures by a *Gynostemma pentaphyllum* extract. *Phytotherapy Research*. 2012, 26(5), 395–401.
144. Xie, Z. et al. Chemical composition of five commercial *Gynostemma pentaphyllum* samples and their radical scavenging, antiproliferative, and anti-inflammatory properties. *Journal of Agricultural and Food Chemistry*. 2010, 58(21), 11243–11249.
145. Wong, W. Y. et al. *Gynostemma pentaphyllum* saponins attenuate inflammation *in vitro* and *in vivo* by inhibition of NF- κ B and STAT3 signaling. *Oncotarget*. 2017, 8(50), 87401–87414.
146. Huyen, V. T. et al. Antidiabetic effect of *Gynostemma pentaphyllum* tea in randomly assigned type 2 diabetic patients. *Hormone and Metabolic Research*. 2010, 42(5), 353–357.
147. Wang, J. et al. Hypoglycemic triterpenes from *Gynostemma pentaphyllum*. *Phytochemistry*. 2018, 155, 171–181.
148. Gou, S. H. et al. Lipid-lowering, hepatoprotective, and atheroprotective effects of the mixture Hong-Qu and gypenosides in hyperlipidemia with NAFLD rats. *Journal of the Chinese Medical Association*. 2016, 79(3), 111–121.
149. Yeo, J. et al. Potential hypoglycemic effect of an ethanol extract of *Gynostemma pentaphyllum* in C57BL/KsJ-db/db mice. *Journal of Medicinal Food*. 2008, 11(4), 709–716.
150. Keilhoff, G. et al. *Gynostemma pentaphyllum* is neuroprotective in a rat model of cardiopulmonary resuscitation. In: *Experimental and Therapeutic Medicine* [online]. 2017, 14(6) [cit. 2021-01-05]. Dostupné z: doi:10.3892/etm.2017.5315
151. Choi, H. S. et al. Anxiolytic effects of herbal ethanol extract from *Gynostemma pentaphyllum* in mice after exposure to chronic stress. In: *Molecules* [online]. 2013, 18(4), 4342–4356 [cit. 2021-12-03]. Dostupné z: doi:10.3390/molecules18044342
152. Li, Y. et al. Anti-cancer effects of *Gynostemma pentaphyllum* (Thunb.) Makino (*Jiaogulan*). *Chinese medicine*. 2016, 11(1), 43.
153. Brinkworth, G. D. a Buckley, J. D. Concentrated bovine colostrum protein supplementation reduces the incidence of self-reported symptoms of upper respiratory tract infection in adult males. *European Journal of Nutrition*. 2003, 42(4), 228–232.
154. Mäkeläinen, H. et al. The effect of beta-glucan on the glycemic and insulin index. *European Journal of Clinical Nutrition*. 2007, 61(6), 779–785.
155. Chen, J. a Raymond, K. Beta-glucans in the treatment of diabetes and associated cardiovascular risks. *Vascular Health and Risk Management*. 2008, 4(6), 1265–1272.
156. Francelino Andrade, E. et al. Effect of beta-glucans in the control of blood glucose levels of diabetic patients: a systematic review. *Nutricion hospitalaria*. 2014, 31(1), 170–177.
157. Bankova, V., de Castro, S. L. a Marcucci, M. C. Propolis: recent advances in chemistry and plant origin. *Apidologie*. 2000, 31(1), 3–15.
158. Grange, J. M. a Davey, R. W. Antibacterial properties of propolis (bee glue). *Journal of the Royal Society of Medicine*. 1990, 83(3), 159–160.
159. Vynograd, N., Vynograd, I. a Sosnowski, Z. A comparative multi-centre study of the efficacy of propolis, acyclovir and placebo in the treatment of genital herpes (HSV). *Phytotherapy Research*. 2000, 14(1), 1–6.
160. Silici, S. et al. Antifungal activities of propolis collected by different races of honeybees against yeasts isolated from patients with superficial mycoses. *Journal of Pharmacological Sciences*. 2005, 99(1), 39–44.
161. Silva-Carvalho, R., Baltazar, F. a Almeida-Aguiar, C. Propolis: A Complex Natural Product with a Plethora of Biological Activities That Can Be Explored for Drug Development. In: *Evidence-Based Complementary and Alternative Medicine* [online]. 2015 [cit. 2021-01-16]. Dostupné z: doi:10.1155/2015/206439
162. Gerster, H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? *International Journal for Vitamin and Nutrition Research*. 1998, 68(3), 159–173.
163. Brenna, J. T. Efficiency of conversion of alpha-linolenic acid to long chain n-3 fatty acids in man. *Current Opinion in Clinical Nutrition & Metabolic Care*. 2002, 5(2), 127–132.

164. Burdge, G. C. a Wootton, S. A. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. *British Journal of Nutrition*. 2002, 88(4):411–420.
165. Plourde, M. a Cunnane, S. C. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. *Applied Physiology, Nutrition, and Metabolism*. 2007, 32(4), 619–634.
166. Chang, C. Y., Ke, D. S. a Chen, J. Y. Essential fatty acids and human brain. *Acta Neurologica Taiwanica*. 2009, 18(4), 231–241.
167. Das, S. et al. Beneficial effects of Fish oil to Human Health- A review. *Agricultural Reviews*. 2009, 30(3), 199–205.
168. Food and Agriculture Organisation of the United Nations (FAO) and World Health Organisation (WHO). Health and nutritional properties of probiotics in food including powder milk with live bacteria. *FAO and WHO Joint and Expert Committee Report*. 2001.
169. Kohout, P. Probiotika v rukou praktického lékaře. *Medicina pro praxi*. 2009, 6(3), 135–139.
170. Ursell, L. K. et al. The intestinal metabolome: an intersection between microbiota and host. *Gastroenterology*. 2014, 146(6), 1470–1476.
171. Baohong, W. et al. The Human Microbiota in Health and Disease. *Engineering*. 2017, 3(1), 71–82.
172. Ganguly, N. K. et al. ICMR-DBT Guidelines for Evaluation of Probiotics in Food. *The Indian Journal of Medical Research*. 2011, 134(1), 22–25.
173. Binda, S. et al. Criteria to Qualify Microorganisms as „Probiotic“ in Foods and Dietary Supplements. In: *Frontiers in Microbiology* [online]. 2020, 11 [cit. 2021-03-18]. Dostupné z: doi:10.3389/fmicb.2020.01662
174. Kligler, B. a Cohns, A. Probiotics. *American Family Physician*. 2008, 78(9), 1073–1078.
175. Heckman, M. A., Weil, J. a Gonzalez de Mejia, E. Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters. *Journal of Food Science*. 2010, 75(3), 77–87.
176. Herden, L. a Weissert, R. The Impact of Coffee and Caffeine on Multiple Sclerosis Compared to Other Neurodegenerative Diseases. *Frontiers in Nutrition*. 2018, 5.
177. Vendramini, L. C. et al. Caffeine intake by patients with autosomal dominant polycystic kidney disease. *Brazilian Journal of Medical and Biological Research*. 2012, 45(9), 834–840.
178. Costill, D. L., Dalsky, G. P. a Fink, W. J. Effects of caffeine ingestion on metabolism and exercise performance. *Medicine & Science in Sports & Exercise*. 1978, 10(3), 155–158.
179. Nehlig, A. a Debry, G. Caffeine and sports activity: a review. *International Journal of Sports Medicine*. 1994, 15(5), 215–223.
180. Fredholm, B. Adenosine, Adenosine Receptors and the Actions of Caffeine. *Pharmacology & Toxicology*. 2009, 76(2), 93–101.
181. Lucas, M. et al. Coffee, caffeine, and risk of completed suicide: results from three prospective cohorts of American adults. *World Journal of Biological Psychiatry*. 2014, 15(5), 377–386.
182. Grosso, G. et al. Coffee, tea, caffeine and risk of depression: A systematic review and dose-response meta-analysis of observational studies. *Molecular Nutrition & Food Research*. 2016, 60(1), 223–234.
183. Flaten, V. et al. From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease? *Biochemical Society Transactions*. 2014, 42(2), 587–592.
184. Qi, H. a Li, S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. *Geriatrics & Gerontology International*. 2014, 14(2), 430–439.
185. Carman, A. J. et al. Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease. *The Journal of Nutrition, Health and Aging*. 2014, 18(4), 383–392.
186. Hashibe, M. et al. Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort. *British Journal of Cancer*. 2015, 113(5), 809–816.
187. Wang, A. et al. Coffee and cancer risk: A meta-analysis of prospective observational studies. *Scientific Reports*. 2016, 6, 33711.
188. Sado, J. et al. Association between coffee consumption and all-sites cancer incidence and mortality. *Cancer Science*. 2017, 108(10), 2079–2087.
189. Zhao, L. G. et al. Coffee drinking and cancer risk: an umbrella review of meta-analyses of observational studies. In: *BMC Cancer* [online]. 2020, 20(1) [cit. 2021-02-01]. Dostupné z: doi: 10.1186/s12885-020-6561-9
190. Hayat, K. et al. Tea and its consumption: Benefits and risks. *Critical Reviews in Food Science and Nutrition*. 2015, 55(7), 939–954.
191. Scharbert, S., Jezussek, M. a Hofmann, T. Evaluation of the taste contribution of theaflavins in black tea infusions using the taste activity concept. *European Food Research and Technology*. 2004, 218(5), 442–447.
192. Vuong, Q. V. et al. Isolation of green tea catechins and their utilisation in the food industry. *Food Reviews International*. 2011, 27(3), 227–247.
193. Wu, C. D. a Wei, G. X. Tea as a functional food for oral health. *Nutrition*. 2002, 18(5), 443–444.
194. Cabrera, C., Artacho, R. a Giménez, R. Beneficial effects of green tea—a review. *Journal of the American College of Nutrition*. 2006, 25(2), 79–99.

195. Dufresne, C. J. a Farnworth, E. R. A review of latest research findings on the health promotion properties of tea. *Journal of Nutritional Biochemistry*. 2001, 12(7), 404–421.
196. Chacko, S. M. et al. Beneficial effects of green tea: a literature review. *Chinese medicine*. 2010, 5, 13.
197. Ruxton, C. H. S. The impact of caffeine on mood, cognitive function, performance and hydration: A review of benefits and risks. *Nutrition Bulletin*. 2008, 33(1), 15–25.
198. Zaveri, N. T. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. *Life Sciences*. 2006, 78(18), 2073–2080.
199. Suzuki, Y., Miyoshi, N. a Isemura, M. Health-promoting effects of green tea. *Proceedings of the Japan Academy. Series B, Physical and Biological Sciences*. 2012, 88(3), 88–101.
200. Park, J. H. et al. Green tea and type 2 diabetes. *Integrative Medicine Research*. 2014, 3(1), 4–10.
201. Pervin, M. et al. Beneficial Effects of Green Tea Catechins on Neurodegenerative Diseases. In: *Molecules* [online]. 2018, 23(6) [cit. 2021-01-02]. Dostupné z: doi:10.3390/molecules23061297
202. Isemura, M. Catechin in Human Health and Disease. *Molecules (Basel, Switzerland)*. 2019, 24(3), 528.
203. Musiał, C., Kuban-Jankowska, A. a Gorska-Ponikowska, M. Beneficial Properties of Green Tea Catechins. *International Journal of Molecular Sciences*. 2020, 21(5), 1744.
204. Meki, A. R., Hamed, E. A. a Ezam, K. A. Effect of green tea extract and vitamin C on oxidant or antioxidant status of rheumatoid arthritis rat model. *Indian Journal of Clinical Biochemistry*. 2009, 24(3), 280–287.
205. Shinichi, K. The Relation between Green Tea Consumption and Cardiovascular Disease as Evidenced by Epidemiological Studies. *The Journal of Nutrition*. 2008, 138 (8), 1548–1553.
206. Miller, P. E. et al. Associations of Coffee, Tea, and Caffeine Intake with Coronary Artery Calcification and Cardiovascular Events. In: *The American Journal of Medicine* [online]. 2017, 130(2) [cit. 2021-01-25]. Dostupné z: doi:10.1016/j.amjmed.2016.08.038
207. Kelly, S. P. et al. L-theanine and caffeine in combination affect human cognition as evidenced by oscillatory alpha-band activity and attention task performance. *Journal of Nutrition*. 2008, 138(8), 1572S–1577S.
208. Dodd, F. L. et al. A double-blind, placebo-controlled study evaluating the effects of caffeine and L-theanine both alone and in combination on cerebral blood flow, cognition and mood. *Psychopharmacology*. 2015, 232(14), 2563–2576.
209. Weinreb, O. et al. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. *Journal of Nutritional Biochemistry*. 2004, 15(9), 506–516.
210. Manděl, S. et al. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. *CNS Neuroscience & Therapeutics*. 2008, 14(4), 352–365.
211. Caruana, M. a Vassallo, N. Tea Polyphenols in Parkinson's Disease. *Advances in Experimental Medicine and Biology*. 2015, 863, 117–137.
212. Gupta, D. A. et al. Green tea: A review on its natural anti-oxidant therapy and cariostatic benefits. *Biological Sciences and Pharmaceutical Research*. 2014, 2, 8–12.
213. Masek, A. Antioxidant and antiradical properties of green tea extract compounds. *International Journal of Electrochemical Science*. 2017, 12(17), 6600–6610.
214. Bernatoniene, J. a Kopustinskiene, D. M. The Role of Catechins in Cellular Responses to Oxidative Stress. *Molecular*. 2018, 23(4), 965.
215. Diepvens, K., Westerterp, K. R. a Westerterp-Plantenga, M. S. Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*. 2007, 292(1), 77–85.
216. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) et al. Scientific opinion on the safety of green tea catechins. In: *EFSA Journal* [online]. 2018, 16(4) [cit. 2021-04-15]. Dostupné z: doi:10.2903/j.efs.2018.5239
217. Schimpl, F. C. et al. Guarana: revisiting a highly caffeinated plant from the Amazon. In: *Journal of Ethnopharmacology* [online]. 2013, 150(1), 14–31 [cit. 2021-04-19]. Dostupné z: doi:10.1016/j.jep.2013.08.023
218. Moustakas, D. et al. Guarana provides additional stimulation over caffeine alone in the planarian model. In: *PloS one* [online]. 2015, 10(4) [cit. 2021-04-19]. Dostupné z: doi:10.1371/journal.pone.0123310
219. Smith, N. a Atroch, A. L. Guaraná's journey from regional tonic to aphrodisiac and global energy drink. *Evidence-Based Complementary and Alternative Medicine*. 2010, 7(3), 279–282.
220. Krewer Cda, C. et al. Habitual intake of guaraná and metabolic morbidities: an epidemiological study of an elderly Amazonian population. *Phytotherapy Research*. 2011, 25(9), 1367–1374.
221. Portella, R. de L. et al. Guaraná (*Paullinia cupana* Kunth) effects on LDL oxidation in elderly people: an *in vitro* and *in vivo* study. In: *Lipids in Health and Diseases* [online]. 2013, 12 [cit. 2020-11-09]. Dostupné z: doi:10.1186/1476-511X-12-12
222. Peixoto, H. et al. Anti-Aging and Antioxidant Potential of *Paullinia cupana* var. *sorbilis*: Findings in *Caenorhabditis elegans* Indicate a New Utilization for Roasted Seeds of Guarana. *Medicines (Basel)*. 2017, 4(3), 61.
223. Lima, N. et al. Modulatory Effects of Guarana (*Paullinia cupana*) on Adipogenesis. *Nutrients*. 2017, 9(6), 635.

224. Lima, N. et al. Guarana (*Paullinia cupana*) Stimulates Mitochondrial Biogenesis in Mice Fed High-Fat Diet. *Nutrients*. 2018, 10(2), 165.
225. Bortolin, R. C. et al. Guarana supplementation attenuated obesity, insulin resistance, and adipokines dysregulation induced by a standardized human Western diet via brown adipose tissue activation. *Phytotherapy Research*. 2019, 33(5), 1394–1403.
226. Kennedy, D. O. et al. Improved cognitive performance and mental fatigue following a multi-vitamin and mineral supplement with added guaraná (*Paullinia cupana*). *Appetite*. 2008, 50(2–3), 506–514.
227. Haskell, C. et al. A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioral effects of guarana in humans. *Journal of Psychopharmacology*. 2017, 21(1), 65–70.
228. Katada, S. et al. Effects of Chlorogenic Acid-Enriched and Hydroxyhydroquinone-Reduced Coffee on Postprandial Fat Oxidation and Antioxidative Capacity in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. *Nutrients*. 2018, 10(4), 525.
229. Heck, C. I. a de Mejia, E. G. Yerba Mate Tea (*Ilex paraguariensis*): a comprehensive review on chemistry, health implications, and technological considerations. *Journal of Food Science*. 2007, 72(9), 138–51.
230. Correa, V. G. et al. Yerba mate aqueous extract improves the oxidative and inflammatory states of rats with adjuvant-induced arthritis. *Food & Function*. 2019, 10(9), 5682–5696.
231. Lutomski, P. et al. Health properties of Yerba Mate. *Annals of Agricultural and Environmental Medicine*. 2020, 27(2), 310–313.
232. Bonakdar, R. A. a Guarneri, E. Coenzyme Q₁₀. *American Family Physician*. 2005, 72(6), 1065–1070.
233. Mizuno, K. et al. Antifatigue effects of coenzyme Q₁₀ during physical fatigue. *Nutrition*. 2008, 24(4), 293–299.
234. Dzugkoev, S. G., Kaloeva, M. B. a Dzugkoeva, F. S. Effect of combination therapy with coenzyme Q₁₀ on functional and metabolic parameters in patients with type 1 diabetes mellitus. *Bulletin of Experimental Biology and Medicine*. 2012, 152(3), 364–366.
235. Soleimani, M. et al. Effects of coenzyme Q₁₀ on the ratio of TH1/TH2 in experimental autoimmune encephalomyelitis model of multiple sclerosis in C57BL/6. *Iranian Biomedical Journal*. 2014, 18(4), 203–211.
236. Jhun, J. et al. Coenzyme Q₁₀ suppresses Th17 cells and osteoclast differentiation and ameliorates experimental autoimmune arthritis mice. *Immunology Letters*. 2015, 166(2), 92–102.
237. Vetvicka, V. a Vetvickova, J. Combination Therapy with Glucan and Coenzyme Q₁₀ in Murine Experimental Autoimmune Disease and Cancer. *Anticancer Research*. 2018, 38(6), 3291–3297.
238. Alehagen, U. et al. Significant Changes in Metabolic Profiles after Intervention with Selenium and Coenzyme Q₁₀ in an Elderly Population. *Biomolecules*. 2019, 9(10), 553.
239. Watts, G. F. et al. Coenzyme Q₁₀ improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. *Diabetologia*. 2002, 45(3), 420–426.
240. Tomasetti, M. et al. Coenzyme Q₁₀ enrichment decreases oxidative DNA damage in human lymphocytes. *Free Radical Biology and Medicine*. 1999, 27(9–10), 1027–1032.
241. Sarter, B. Coenzyme Q₁₀ and cardiovascular disease: a review. *Journal of Cardiovascular Nursing*. 2002, 16(4), 9–20.
242. Zozina, V. I. et al. Coenzyme Q₁₀ in Cardiovascular and Metabolic Diseases: Current State of the Problem. *Current Cardiology Reviews*. 2018, 14(3), 164–174.
243. Martelli, A. et al. Coenzyme Q₁₀: Clinical Applications in Cardiovascular Diseases. *Antioxidants (Basel, Switzerland)*. 2020, 9(4), 341.
244. Langsjoen, H. et al. Usefulness of coenzyme Q₁₀ in clinical cardiology: a long-term study. *Molecular Aspects of Medicine*. 1994, 15 Suppl., S165–S175.
245. Jafari, M. et al. Coenzyme Q₁₀ in the treatment of heart failure: A systematic review of systematic reviews. *Indian Heart Journal*. 2018, 70 (Suppl 1), S111–S117.
246. Bhatt, K. N. a Butler, J. Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials. *Current Heart Failure Reports*. 2018, 15(3), 191–197.
247. Dai, Y. L. et al. Reversal of mitochondrial dysfunction by coenzyme Q₁₀ supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial. *Atherosclerosis*. 2011, 216(2), 395–401.
248. Cooke, M. et al. Effects of acute and 14-day coenzyme Q₁₀ supplementation on exercise performance in both trained and untrained individuals. *Journal of the International Society of Sports Nutrition*. 2008, 5.
249. Siebrecht, S. et al. Coenzyme Q₁₀ and ubiquinol for physical performance [online]. 2015 [cit. 2021-02-14]. Dostupné z: https://www.researchgate.net/publication/296951483_Coenzyme_Q10_and_ubiquinol_for_physical_performance
250. Suzuki, Y. et al. Ubiquinol-10 supplementation alleviates tissue damage in muscle and fatigue caused by strenuous exercise in male distance runners. *International Journal for Vitamin and Nutrition Research*. 2020, 31, 1–10.
251. Karlsson, J. et al. Ubiquinone and alpha tocopherol in plasma; means of translocation or depot. *Journal of Clinical Investigation*. 1993, 71 (8 Suppl), 84–91.

252. Battino, M. et al. Metabolic and antioxidant markers in the plasma of sportsmen from a Mediterranean town performing non-agonistic activity. *Molecular Aspects of Medicine*. 1997, 18(1), 241–245.
253. Liao, P. et al. Effects of coenzyme Q₁₀ supplementation on liver mitochondrial function and aerobic capacity in adolescent athletes. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2007, 23(4), 491–494.
254. Guescini, M., et al. The Combination of Physical Exercise with Muscle-Directed Antioxidants to Counteract Sarcopenia: A Biomedical Rationale for Pleiotropic Treatment with Creatine and Coenzyme Q₁₀. In: *Oxidative Medicine and Cellular Longevity* [online]. 2017 [cit. 2021-04-20]. Dostupné z: doi:10.1155/2017/7083049
255. Dahri, M. et al. Oral coenzyme Q₁₀ supplementation in patients with migraine: Effects on clinical features and inflammatory markers. *Nutritional Neuroscience*. 2019, 22(9), 607–615.
256. Shoeibi, A. et al. Effectiveness of coenzyme Q₁₀ in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. *Acta Neurologica Belgica*. 2017, 117(1), 103–109.
257. Žmitek, K. et al. The effect of dietary intake of coenzyme Q₁₀ on skin parameters and condition: Results of a randomised, placebo-controlled, double-blind study. *Biofactors*. 2017, 43(1), 132–140.
258. Gvozdjaková, A. et al. Mitochondriálna kardiológia. *Cardiology letters*. 2017, 26(3), 145–163.
259. Buciuman, C. a Vicas, L. Dietary supplements – Bioactive principles: Regulatory aspects, *in vitro* release profiles – Coenzyme Q₁₀. *Studia Universitatis Vasile Goldis Arad, Seria Stiintele Vietii*. 2017, 27(4), 221–230.
260. PDQ Cancer Information Summaries [online]. Bethesda (MD): National Cancer Institute (US). 2002 [cit. 2021-02-11]. Dostupné z: <https://www.ncbi.nlm.nih.gov/books/NBK82221/>
261. Poly, C. et al. The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort. *The American Journal of Clinical Nutrition*. 2011, 94(6), 1584–1591.
262. Spiers, P. A. et al. Citicoline improves verbal memory in aging. *Archives of Neurology*. 1996, 53(5), 441–448.
263. Gibson, G. E. a Peterson, C. Aging decreases oxidative metabolism and the release and synthesis of acetylcholine. *Journal of Neurochemistry*. 1981, 37(4), 978–984.
264. Blusztajn, J. K., Slack, B. E. a Mellott, T. J. Neuroprotective Actions of Dietary Choline. *Nutrients*. 2017, 9(8), 815.
265. Mourad, A. M. et al. Influence of soy lecithin administration on hypercholesterolemia. In: *Cholesterol* [online]. 2010 [cit. 2021-02-20]. Dostupné z: doi:10.1155/2010/824813
266. Kato-Kataoka, A. et al. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. *Journal of Clinical Biochemistry and Nutrition*. 2010, 47(3), 246–255.
267. Parker, A. G. et al. The effects of IQPLUS Focus on cognitive function, mood and endocrine response before and following acute exercise. *Journal of the International Society of Sports Nutrition*. 2011, 8(1), 16.
268. Crook, T. et al. Effects of phosphatidylserine in Alzheimer's disease. *Psychopharmacology Bulletin*. 1992, 28(1), 61–66.
269. Engel, R. R. et al. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. *European Neuropsychopharmacology*. 1992, 2(2), 149–155.
270. Richter, Y. et al. The effect of soybean-derived phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study. *Clinical Interventions in Aging*. 2013, 8, 557–563.
271. Stough, C., Singh, H. a Zangara, A. Mechanisms, Efficacy, and Safety of *Bacopa monnieri* (Brahmi) for Cognitive and Brain Enhancement. In: *Evidence-Based Complementary and Alternative Medicine* [online]. 2015 [cit. 2020-11-09]. Dostupné z: doi:10.1155/2015/717605
272. Roodenrys, S. et al. Chronic effects of Brahmi (*Bacopa monnieri*) on human memory. *Neuropsychopharmacology*. 2002, 27(2), 279–281.
273. Aguiar, S. a Borowski, T. Neuropharmacological review of the nootropic herb *Bacopa monnieri*. *Rejuvenation Research*. 2013, 16(4), 313–326.
274. Chaudhari, K. S. et al. Neurocognitive Effect of Nootropic Drug *Brahmi* (*Bacopa monnieri*) in Alzheimer's Disease. *Annals of Neurosciences*. 2017, 24(2), 111–122.
275. Singh, H. K. a Dhawan, B. N. Neuropsychopharmacological effects of the Ayurvedic nootropic *Bacopa monnieri* Linn. (Brahmi)". *Indian Journal of Pharmacology*. 1997, 29(5), 359–365.
276. Martis, G., Rao, A. a Karanth, K. S. Neuropharmacological activity of *Herpestis monniera*. *Fitoterapia*. 1992, 63(5), 399–404.
277. Raghav, S. et al. Randomized controlled trial of standardized *Bacopa monnieri* extract in age-associated memory impairment. *Indian Journal of Psychiatry*. 2006, 48(4), 238–242.
278. Calabrese, C. et al. Effects of a Standardized *Bacopa monnieri* Extract on Cognitive Performance, Anxiety, and Depression in the Elderly: A Randomized, Double-Blind, Placebo-Controlled Trial. *Journal of Alternative and Complementary Medicine*. 2008, 14(6), 707–713.
279. Morgan, A. a Stevens, J. Does *Bacopa monnieri* improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. *Journal of Alternative and Complementary Medicine*. 2010, 16(7), 753–759.
280. Uabundit, N. et al. Cognitive enhancement and neuroprotective effects of *Bacopa monnieri* in Alzheimer's disease model. *Journal of Ethnopharmacology*. 2010, 127(1), 26–31.

281. Pase, M. P. et al. The cognitive-enhancing effects of *Bacopa monnieri*: a systematic review of randomized, controlled human clinical trials. *The Journal of Alternative and Complementary Medicine*. 2012, 18(7), 647–652.
282. Valverde, M. E., Hernández-Pérez, T. a Paredes-López, O. Edible mushrooms: improving human health and promoting quality life. In: *International Journal of Microbiology* [online]. 2015 [cit. 2020-10-23]. Dostupné z: doi:10.1155/2015/376387
283. Zhang, J. J. et al. Bioactivities and Health Benefits of Mushrooms Mainly from China. *Molecules (Basel, Switzerland)*. 2016, 21(7), 938.
284. Jayachandran, M., Xiao, J. a Xu, B. A Critical Review on Health Promoting Benefits of Edible Mushrooms through Gut Microbiota. *International Journal of Molecular Sciences*. 2017, 18(9), 1934.
285. Wachtel-Galor, S. a Benzie, I. F. F. *Herbal Medicine: Biomolecular and Clinical Aspects*. Second Edition, Boca Raton (FL): CRC Press/Taylor & Francis, 2011. ISBN 978-1-4398-0713-2.
286. Pan, K. et al. Optimization extraction of *Ganoderma lucidum* polysaccharides and its immunity and antioxidant activities. *International Journal of Biological Macromolecules*. 2013, 55, 301–306.
287. Jin, X. et al. *Ganoderma lucidum* (Reishi mushroom) for cancer treatment. In: *The Cochrane Database of Systematic Reviews* [online]. 2016 [cit. 2021-01-05]. Dostupné z: doi:10.1002/14651858.CD007731.pub3
288. Ajith, T. A. et al. Effect of *Ganoderma lucidum* on the activities of mitochondrial dehydrogenases and complex I and II of electron transport chain in the brain of aged rats. *Experimental Gerontology*. 2009, 44(3), 219–223.
289. Smina, T. P. et al. *Ganoderma lucidum* total triterpenes prevent radiation-induced DNA damage and apoptosis in splenic lymphocytes *in vitro*. *Mutation Research*. 2011, 726(2), 188–194.
290. Orhan, I. et al. Screening of various phenolic acids and flavonoid derivatives for their anticholinesterase potential. *Zeitschrift für Naturforschung. C, Journal of biosciences*. 2007, 62(11–12), 829–832.
291. Hasnat, A., Pervin, M. a Lim, B. O. Acetylcholinesterase inhibition and *in vitro* and *in vivo* antioxidant activities of *Ganoderma lucidum* grown on germinated brown rice. In: *Molecules* [online]. 2013, 18(6), 6663–6678. [cit. 2021-11-09]. Dostupné z: doi:10.3390/molecules18066663
292. Cör, D. et al., Two-stage extraction of antitumor, antioxidant and antiacetylcholinesterase compounds from *Ganoderma lucidum* fruiting body. *The Journal of Supercritical Fluids*. 2014, 91, 53–60.
293. Zhang, X. Q. et al. Triterpenoids with neurotrophic activity from *Ganoderma lucidum*. *Natural Product Research*. 2011, 25(17), 1607–1613.
294. Paydary, K. et al. The emergence of drug resistant HIV variants and novel anti-retroviral therapy. *Asian Pacific Journal of Tropical Biomedicine*. 2013, 3(7), 515–522.
295. Shevelev, O. B. et al. Hypotensive and neurometabolic effects of intragastric Reishi (*Ganoderma lucidum*) administration in hypertensive ISIAH rat strain. *Phytomedicine*. 2018, 41, 1–6.
296. Rahman, M. A., Abdullah, N. a Aminudin, N. Evaluation of the Antioxidative and Hypo-cholesterolemic Effects of Lingzhi or Reishi Medicinal Mushroom, *Ganoderma lucidum* (Agaricomycetes), in Ameliorating Cardiovascular Disease. *International Journal of Medicinal Mushrooms*. 2018, 20(10), 961–969.
297. Klupp, N. L. et al. *Ganoderma lucidum* mushroom for the treatment of cardiovascular risk factors. In: *Cochrane database of systematic reviews* [online]. 2015. [cit. 2021-01-17]. Dostupné z: doi:10.1002/14651858.CD007259.pub2
298. Patel, S. a Goyal, A. Recent developments in mushrooms as anti-cancer therapeutics: a review. *3 Biotech*. 2012, 2(1), 1–15.
299. Wang, H. et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. *Cancer Medicine*. 2017, 6(10), 2222–2233.
300. Lindequist, U., Niedermeyer, T. H. a Jülich, W. D. The pharmacological potential of mushrooms. *Evidence-based complementary and alternative medicine*. 2005, 2(3), 285–299.
301. Ina, K., Kataoka, T. a Ando, T. The use of lentinan for treating gastric cancer. *Anti-Cancer Agents in Medicinal Chemistry*. 2013, 13(5), 681–688.
302. Huang, X. a Nie, S. The structure of mushroom polysaccharides and their beneficial role in health. *Food & Function*. 2015, 6(10), 3205–3217.
303. Wu, J. et al. Mechanisms underlying the effect of polysaccharides in the treatment of type 2 diabetes: A review. *Carbohydrate Polymers*. 2016, 144, 474–494.
304. Ganesan, K. a Xu, B. Anti-Diabetic Effects and Mechanisms of Dietary Polysaccharides. In: *Molecules* [online]. 2019, 24(14) [cit. 2021-02-13]. Dostupné z: doi:10.3390/molecules24142556
305. Yang, S. et al. Alkali-soluble polysaccharides from mushroom fruiting bodies improve insulin resistance. *International Journal of Biological Macromolecules*. 2019, 126, 466–474.
306. Enman, J., Rova, U. a Berglund, K. A. Quantification of the bioactive compound eritadenine in selected strains of shiitake mushroom (*Lentinus edodes*). *Journal of Agricultural and Food Chemistry*. 2007, 55(4), 1177–1180.
307. Hobbs, C. *Medicinal Mushrooms: An Exploration of Tradition, Healing, & Culture (Herbs and Health Series)*. Botanica Press, 2002. ISBN 978-1570671432.
308. Akamatsu, S. et al. Hepatoprotective effect of extracts from *Lentinus edodes* mycelia on dimethylnitrosamine-induced liver injury. *Biological and Pharmaceutical Bulletin*. 2004, 27(12), 1957–1960.

309. Bisen, P. S. et al. *Lentinus edodes*: a macrofungus with pharmacological activities. *Current Medicinal Chemistry*. 2010, 17(22), 2419–2430.
310. Navrátilová, Z. Šiitake – obsahové látky a léčivé účinky. *Praktické lékařství*. 2015, 11(1), 23–24.
311. Powell, M. *Medicinal Mushrooms – The Essential Guide*. Second Edition, Eastbourne: Mycology Press, 2013. ISBN 978-0956689818.
312. Konno, S. Synergistic potentiation of D-fraction with vitamin C as possible alternative approach for cancer therapy. *International Journal of General Medicine*. 2009, 2, 91–108.
313. Nanba, H. Maitake D-fraction: healing and preventing potentials for cancer. *Townsend Letter*. 1996, 151/152, 84–85.
314. Manohar, V. et al. Effect of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice. *Diabetes, Obesity and Metabolism*. 2002, 4(1), 43–48.
315. Kubo, K. a Nanba, H. Anti-hyperliposis effect of Maitake fruit body (*Grifola frondosa*). *Biological and Pharmaceutical Bulletin*. 1997, 20(7), 781–785.
316. Kabir, Y. a Kimura, S. Dietary mushrooms reduce blood pressure in spontaneously hypertensive rats (SHR). *Journal of Nutritional Science and Vitaminology (Tokyo)*. 1989, 35(1), 91–94.
317. Inoue, A., Kodama, N. a Nanba, H. Effect of Maitake (*Grifola frondosa*) D-Fraction on the Control of the T Lymph Node Th-1/Th-2 Proportion. *Biological & pharmaceutical bulletin*. 2002, 25(4), 536–540.
318. Kodama, N. et al. Effect of Maitake (*Grifola frondosa*) D-Fraction on the Activation of NK Cells in Cancer Patients. *Journal of Medicinal Food*. 2003, 6(4), 371–377.
319. Ashraf, S. A. et al. Cordycepin for Health and Wellbeing: A Potent Bioactive Metabolite of an Entomopathogenic Medicinal Fungus *Cordyceps* with Its Nutraceutical and Therapeutic Potential. In: *Molecules* [online]. 2020, 25(12) [cit. 2021-01-09]. Dostupné z: doi:10.3390/molecules25122735
320. Zhou, X. et al. Cordycepin is an immunoregulatory active ingredient of *Cordyceps sinensis*. *The American Journal of Chinese Medicine*. 2008, 36(5), 967–980.
321. Wang, Z. M. et al. Structural characterisation and immunomodulatory property of an acidic polysaccharide from mycelial culture of *Cordyceps sinensis* fungus Cs-HK1. *Food Chemistry*. 2011, 125(2), 637–643.
322. Lee, B. et al. *Cordyceps militaris* improves neurite outgrowth in neuro2A cells and reverses memory impairment in rats. *Food Science and Biotechnology*. 2011, 20, 1599–1608.
323. Zhang, X. L. et al. *Cordyceps sinensis* decreases TGF- β 1 dependent epithelial to mesenchymal transdifferentiation and attenuates renal fibrosis. *Food Hydrocolloids*. 2012, 28, 200–212.
324. Zhu, J. S., Halpern, G. M. a Jones, K. The scientific rediscovery of a precious ancient Chinese herbal regimen: *Cordyceps sinensis*: part II. *Journal of Alternative and Complementary Medicine*. 1998, 4(4), 429–457.
325. Tomohiro, C. et al. Effects of extracts from *Cordyceps sinensis* on M1 muscarinic acetylcholine receptor *in vitro* and *in vivo*. *Journal of Receptor, Ligand and Channel Research*. 2010, 2010(3), 97–104.
326. Yuan, R. et al. Protective effect of acidic polysaccharide from *Schisandra chinensis* on acute ethanol-induced liver injury through reducing CYP2E1-dependent oxidative stress. In: *Biomedicine & Pharmacotherapy* [online]. 2018, 99, 537–542 [cit. 2020-11-05]. Dostupné z: doi:10.1016/j.biopha.2018.01.079
327. Dai, G. et al. CordyMax™ Cs-4 improves steady-state bioenergy status in mouse liver. *Journal of Alternative and Complementary Medicine*. 2001, 7(3), 231–240.
328. Siu, K. M. et al. Pharmacological basis of 'Yin-nourishing' and 'Yang-invigorating' actions of *Cordyceps*, a Chinese tonifying herb. *Life Sciences*. 2004, 76(4), 385–395.
329. Yi, X., Xi-zhen, H. a Zhu, J. S. Randomized double-blind placebo-controlled clinical trial and assessment of fermentation product of *Cordyceps sinensis* (Cs4) in enhancing aerobic capacity and respiratory function of the healthy elderly volunteers. *Chinese Journal of Integrative Medicine*. 2004, 10(3), 187–192.
330. Hawkins, M. N. et al. Maximal oxygen uptake as a parametric measure of cardiorespiratory capacity. *Medicine & Science in Sports & Exercise*. 2007, 39(1), 103–107.
331. Xu, Y. F. Effect of Polysaccharide from *Cordyceps militaris* (Ascomycetes) on Physical Fatigue Induced by Forced Swimming. *International Journal of Medicinal Mushrooms*. 2016, 18(12), 1083–1092.
332. Hirsch, K. R. et al. *Cordyceps militaris* Improves Tolerance to High-Intensity Exercise After Acute and Chronic Supplementation. *Journal of Dietary Supplements*. 2017, 14(1), 42–53.
333. Abrams, D. I. et al. Antihyperlipidemic effects of *Pleurotus ostreatus* (oyster mushrooms) in HIV-infected individuals taking antiretroviral therapy. *BMC complementary and alternative medicine*. 2011, 11, 60.
334. Bobek, P., Ozdin, L. a Kajaba, I. Dose-dependent hypocholesterolaemic effect of oyster mushroom (*Pleurotus ostreatus*) in rats. *Physiological Research*. 1997, 46(4), 327–329.
335. Harris, R. C., Söderlund, K. a Hultman, E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. *Clinical Science (Lond)*. 1992, 83(3), 367–374.
336. Balsom, P. D., Söderlund, K. a Ekblom, B. Creatine in humans with special reference to creatine supplementation. *Sports Medicine*. 1994, 18(4), 268–280.
337. Hultman, E. et al. Muscle creatine loading in men. *Journal of Applied Physiology (1985)*. 1996, 81(1), 232–237.
338. Demant, T. W. a Rhodes, E. C. Effects of creatine supplementation on exercise performance. *Sports Medicine*. 1999, 28(1), 49–60.

339. Kreider, R. B. et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. *Journal of the International Society of Sports Nutrition*. 2017, 14, 18.
340. Chrusch, M. J. et al. Creatine supplementation combined with resistance training in older men. *Medicine & Science in Sports & Exercise*. 2001, 33(12), 2111-2117.
341. Branch, J. D. Effect of creatine supplementation on body composition and performance: a meta-analysis. *International Journal of Sport Nutrition and Exercise Metabolism*. 2003, 13(2), 198-226.
342. Chilibeck, P. D. et al. Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis. *Open Access Journal of Sports Medicine*. 2017, 8, 213-226.
343. Wyss, M. a Schulze, A. Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease? *Neuroscience*. 2002, 112(2), 243-260.
344. Smith, R. N., Agharkar, A. S. a Gonzales, E. B. A review of creatine supplementation in age-related diseases: more than a supplement for athletes. In: *F1000Res* [online]. 2014, 3, 222 [cit. 2020-09-03]. Dostupné z: doi:10.12688/f1000research.5218.1
345. Terjung, R. L. et al. American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. *Medicine & Science in Sports & Exercise*. 2000, 32(3), 706-717.
346. Rawson, E. S. a Volek, J. S. Effects of creatine supplementation and resistance training on muscle strength and weightlifting performance. *The Journal of Strength and Conditioning Research*. 2003, 17(4), 822-831.
347. Buford, T. et al. International Society of Sports Nutrition position stand: creatine supplementation and exercise. In: *Journal of the International Society of Sports Nutrition* [online]. 2007, 4:6 [cit. 2020-09-29]. Dostupné z: doi:10.1186/1550-2783-4-6
348. Green, A. L. et al. Carbohydrate ingestion augments skeletal muscle creatine accumulation during creatine supplementation in humans. In: *American Journal of Physiology* [online]. 1996, (5 Pt 1), 821-826 [cit. 2021-02-03]. Dostupné z: doi:10.1152/ajpendo.1996.271.5.E821
349. Steenge, G. R., Simpson, E. J. a Greenhaff, P. L. Protein- and carbohydrate-induced augmentation of whole body creatine retention in humans. *Journal of Applied Physiology (1985)*. 2000, 89(3), 1165-1171.
350. Kreider, R. B. Effects of creatine supplementation on performance and training adaptations. *Molecular and Cellular Biochemistry*. 2003, 244(1-2), 89-94.
351. Jagim, A. R. a Kerksick, C. M. Creatine Supplementation in Children and Adolescents. *Nutrients*. 2021, 13(2), 664.
352. Richter, M. et al. Revised Reference Values for the Intake of Protein. *Annals of Nutrition & Metabolism*. 2019, 74(3), 242-250.
353. Pramuková, B., Szabadosová, V. a Šoltéssová, A. Current knowledge about sports nutrition. *The Australasian Medical Journal*. 2011, 4(3), 107-110.
354. Jäger, R. et al. International Society of Sports Nutrition Position Stand: protein and exercise. *Journal of the International Society of Sports Nutrition*. 2017, 14.
355. Stokes, T. et al. Recent Perspectives Regarding the Role of Dietary Protein for the Promotion of Muscle Hypertrophy with Resistance Exercise Training. *Nutrients*. 2018, 10(2), 180.
356. Carbone, J. W. a Pasiakos, S. M. Dietary Protein and Muscle Mass: Translating Science to Application and Health Benefit. In: *Nutrients* [online]. 2019, 11(5) [cit. 2020-10-27]. Dostupné z: doi:10.3390/nu11051136
357. Moore, D. R. et al. Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men. *The American Journal of Clinical Nutrition*. 2009, 89(1), 161-168.
358. Staples, A. W. et al. Carbohydrate does not augment exercise-induced protein accretion versus protein alone. *Medicine & Science in Sports & Exercise*. 2011, 43(7), 1154-1161.
359. Aragon, A. A. a Schoenfeld, B. J. Nutrient timing revisited: is there a post-exercise anabolic window? *Journal of the International Society of Sports Nutrition*. 2013, 10(1), 5.
360. Schoenfeld, B. J. et al. Pre- versus post-exercise protein intake has similar effects on muscular adaptations. In: *PeerJ* [online]. 2017, 5 [cit. 2021-01-04]. Dostupné z: doi:10.7717/peerj.2825
361. Tarnopolsky, M. Protein requirements for endurance athletes. *Nutrition*. 2004, 20(7-8), 662-668. Kato, H. et al. Protein Requirements Are Elevated in Endurance Athletes after Exercise as Determined by the Indicator Amino Acid Oxidation Method. In: *PLoS One* [online]. 2016, 11(6) [cit. 2020-11-23]. Dostupné z: doi:10.1371/journal.pone.0157406
362. Kerksick, C. M. et al. International society of sports nutrition position stand: nutrient timing. *Journal of the International Society of Sports Nutrition*. 2017, 14, 33.
363. Knuiiman, P. et al. Protein and the Adaptive Response With Endurance Training: Wishful Thinking or a Competitive Edge? *Frontiers in Physiology*. 2018, 9, 598.
364. Cintineo, H. P. et al. Effects of Protein Supplementation on Performance and Recovery in Resistance and Endurance Training. In: *Frontiers in Physiology* [online]. 2019, 115 [cit. 2020-08-18]. Dostupné z: doi:10.3389/fnut.2018.00083
365. Mata, F. et al. Carbohydrate Availability and Physical Performance: Physiological Overview and Practical Recommendations. *Nutrients*. 2019, 11(5), 1084.

366. Churchward-Venne, T. A. et al. Dose-response effects of dietary protein on muscle protein synthesis during recovery from endurance exercise in young men: a double-blind randomized trial. *The American Journal of Clinical Nutrition*. 2020, 112(2), 303-317.
367. Al Alawi, A. M., Majoni, S. W. a Falhammar, H. Magnesium and Human Health: Perspectives and Research Directions. *International Journal of Endocrinology*. 2018.
368. Marx, A. a Neutra, R. R. Magnesium in drinking water and ischemic heart disease. *Epidemiologic Reviews*. 1997, 19(2), 258-72.
369. Zadák, Z., Tichá, A. a Hyšpler, R. Suplementace hořčičku - farmakologické mechanismy, metody podání a pasty. *Klinická farmakologie a farmacie*. 2017, 31(3), 16-18.
370. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. *Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride*. Washington, DC: National Academies Press, 1997.
371. De Baaij, J. H., Hoenderop, J. G. a Bindels, R. J. Magnesium in man: implications for health and disease. *Physiological Reviews*. 2015, 95(1), 1-46.
372. Zhang, Y. et al. Can Magnesium Enhance Exercise Performance? *Nutrients*. 2017, 9(9), 946.
373. Nielsen, F. H. a Lukaski, H. C. Update on the relationship between magnesium and exercise. *Magnesium Research*. 2006, 19(3), 180-189.
374. Kass, L. S. a Poeira, F. The effect of acute vs chronic magnesium supplementation on exercise and recovery on resistance exercise, blood pressure and total peripheral resistance on normotensive adults. *Journal of the International Society of Sports Nutrition*. 2015, 12, 19.
375. Córdova, A. et al. Impact of Magnesium Supplementation in Muscle Damage of Professional Cyclists Competing in a Stage Race. *Nutrients*. 2019, 11(8).
376. Gröber, U., Schmidt, J. a Kisters, K. Magnesium in Prevention and Therapy. *Nutrients*. 2015, 7(9), 8199-8226.
377. Barbagallo, M. a Dominguez, L. J. Magnesium and type 2 diabetes. *World Journal of Diabetes*. 2015, 6(10), 1152-1157.
378. Mauskop, A. a Altura, B. M. Role of magnesium in the pathogenesis and treatment of migraines. *Journal of Clinical Neuroscience*. 1998, 5(1), 24-27.
379. Chiu, H. Y. et al. Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials. In: *Pain Physician* [online]. 2016, 19(1) [cit. 2021-03-03]. Dostupné z: PMID:26752497
380. Von Luckner, A. a Riederer, F. Magnesium in Migraine Prophylaxis-Is There an Evidence-Based Rationale? A Systematic Review. *Headache*. 2018, 58(2), 199-209.
381. Dolati, S. et al. The Role of Magnesium in Pathophysiology and Migraine Treatment. *Biological Trace Element Research*. 2020, 196(2), 375-383.
382. Maier, J. A. et al. Headaches and Magnesium: Mechanisms, Bioavailability, Therapeutic Efficacy and Potential Advantage of Magnesium Pidolate. *Nutrients*. 2020, 12(9), 2660.
383. Maizels, M., Blumenfeld, A. a Burchette, R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. *Headache*. 2004, 44(9), 885-890.
384. Gaul, C. et al. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q₁₀: a randomized, placebo-controlled, double-blind, multicenter trial. *The Journal of Headache and Pain*. 2015, 16.
385. Razak, M. A. et al. Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. In: *Oxidative Medicine and Cellular Longevity* [online]. 2017 [cit. 2020-11-01]. Dostupné z: doi:10.1155/2017/1716701
386. Abbasi, B. et al. The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial. *Journal of Research in Medical Sciences*. 2012, 17(12), 1161-1169.
387. Wang, J. et al. Magnesium L-threonate prevents and restores memory deficits associated with neuropathic pain by inhibition of TNF- α . In: *Pain Physician Journal* [online]. 2013, 16(5), 563-575 [cit. 2021-01-01]. Dostupné z: doi:10.36076/ppj.2013/16/E563
388. Kim, Y. S. et al. Neuroprotective Effects of Magnesium L-threonate in a Hypoxic Zebrafish Model. *BMC Neuroscience*. 2020, 21, 29.
389. Nařízení Evropského parlamentu a Rady (EU) č. 1169/2011 ze dne 25. října 2011 o poskytování informací o potravinách spotřebitelům, o změně nařízení Evropského parlamentu a Rady (ES) č. 1924/2006 a (ES) č. 1925/2006 a o zrušení směrnice Komise 87/250/EHS, směrnice Rady 90/496/EHS, směrnice Komise 1999/10/ES, směrnice Evropského parlamentu a Rady 2000/13/ES, směrnice Komise 2002/67/ES a 2008/5/ES a nařízení Komise (ES) č. 608/2004. In: *Úřední věstník Evropské unie*. 2011. ISSN 1725-5163.
390. Yablon, L. A. a Mauskop, A. *Magnesium in the Central Nervous System*. Adelaide (AU): University of Adelaide Press, 2011. ISBN 978-0987073068.
391. Everaert, I. et al. Vegetarianism, female gender and increasing age, but not CNBP₁ genotype, are associated with reduced muscle carnosine levels in humans. *Amino Acids*. 2011, 40(4), 1221-1229.
392. Gross, M. et al. Effects of beta-alanine supplementation and interval training on physiological determinants of severe exercise performance. *European Journal of Applied Physiology*. 2014, 114(2), 221-234.

393. Harris, R. C. et al. The absorption of orally supplied beta-alanine and its effect on muscle carnosine synthesis in human vastus lateralis. *Amino Acids*. 2006, 30(3), 279–289.
394. Hill, C. A. et al. Influence of beta-alanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. *Amino Acids*. 2007, 32(2), 225–233.
395. Sale, C., Saunders, B. a Harris, R. C. Effect of beta-alanine supplementation on muscle carnosine concentrations and exercise performance. In: *Amino Acids* [online]. 2010, 39(2), 321–333 [cit. 2021-02-19]. Dostupné z: doi:10.1007/s00726-009-0443-4
396. Hobson, R. M. et al. Effects of β -alanine supplementation on exercise performance: a meta-analysis. *Amino acids*. 2012, 43(1), 25–37.
397. Everaert, I. et al. Effect of beta-alanine and carnosine supplementation on muscle contractility in mice. *Medicine & Science in Sports & Exercise*. 2013, 45(1), 43–51.
398. Hoffman, J. et al. Effect of creatine and beta-alanine supplementation on performance and endocrine responses in strength/power athletes. *International Journal of Sport Nutrition and Exercise Metabolism*. 2006, 16(4), 430–446.
399. Stout, J. R. et al. Effects of twenty-eight days of beta-alanine and creatine monohydrate supplementation on the physical working capacity at neuromuscular fatigue threshold. *The Journal of Strength and Conditioning Research*. 2006, 20(4), 928–931.
400. Stellingwerff, T. et al. Effect of two β -alanine dosing protocols on muscle carnosine synthesis and washout. In: *Amino Acids* [online]. 2012, 42(6), 2461–2472 [cit. 2021-02-19]. Dostupné z: doi:10.1007/s00726-011-1054-4
401. Furst, T. et al. β -Alanine supplementation increased physical performance and improved executive function following endurance exercise in middle aged individuals. *Journal of the International Society of Sports Nutrition*. 2018, 15(1), 32.
402. Stohs, S. J. Safety, Efficacy, and Mechanistic Studies Regarding *Citrus aurantium* (Bitter Orange) Extract and *p*-Synephrine. *Phytotherapy Research*. 2017, 31(10), 1463–1474.
403. Haaz, S. et al. *Citrus aurantium* and synephrine alkaloids in the treatment of overweight and obesity: an update. *Obesity Reviews*. 2006, 7(1), 79–88.
404. Stohs, S. J. et al. Effects of *p*-synephrine alone and in combination with selected bioflavonoids on resting metabolism, blood pressure, heart rate and self-reported mood changes. *International Journal of Medical Sciences*. 2011, 8(4), 295–301.
405. Gutiérrez-Hellín, J. a Del Coso, J. Acute *p*-synephrine ingestion increases fat oxidation rate during exercise. *British Journal of Clinical Pharmacology*. 2016, 82(2), 362–368.
406. Kaats, G. R. a Stohs, S. J. Increased eating control and energy levels associated with consumption of a bitter orange (*p*-synephrine) extract chew—a randomized placebo controlled study. *Nutrition and Dietary Supplements*. 2017, 9, 29–35.
407. Westerterp-Plantenga, M. S. a Kovacs, E. M. The effect of (-)-hydroxycitrate on energy intake and satiety in overweight humans. *International Journal of Obesity and Related Metabolic Disorders*. 2002, 26(6), 870–872.
408. Roy, S. et al. Body weight and abdominal fat gene expression profile in response to a novel hydroxycitric acid-based dietary supplement. *Gene Expression*. 2004, 11(5–6), 251–262.
409. Kim, Y. J. et al. A mixture of the aqueous extract of *Garcinia cambogia*, soy peptide and L-carnitine reduces the accumulation of visceral fat mass in rats rendered obese by a high fat diet. *Genes & Nutrition*. 2008, 2(4), 353–358.
410. Chuah, L. O. et al. Updates on Antiobesity Effect of *Garcinia* Origin (-)-HCA. In: *Evidence-Based Complementary and Alternative Medicine* [online]. 2013 [cit. 2021-03-16]. Dostupné z: doi:10.1155/2013/751658
411. Preuss, H. G. et al. An overview of the safety and efficacy of a novel, natural(-)-hydroxycitric acid extract (HCA-SX) for weight management. *Journal of Medicinal Chemistry*. 2004, 35(1–6), 33–48.
412. Downs, B. W. et al. Bioefficacy of a novel calcium-potassium salt of (-)-hydroxycitric acid. *Mutation Research*. 2005, 579(1–2), 149–62.
413. Raina, R. et al. *Garcinia cambogia*. In: *Nutraceuticals (book)* [online]. 2016 [cit. 2020-10-20]. Dostupné z: doi:10.1016/B978-0-12-802147-7.00048-6
414. Yamada, T., Hida, H. a Yamada, Y. Chemistry, physiological properties, and microbial production of hydroxycitric acid. *Applied Microbiology and Biotechnology*. 2007, 75(5), 977–982.
415. Rahman, W. et al. Evidence of *Garcinia cambogia* as a fat burning and appetite suppressing agents. *Archives of Pharmacy Practice*. 2016, 7(5), 22.
416. Kim, Y. J. et al. *Garcinia Cambogia* attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. *World Journal of Gastroenterology*. 2013, 19(29), 4689–4701.
417. Sripradha, R. a Magadi, S. G. Efficacy of *Garcinia Cambogia* on Body Weight, Inflammation and Glucose Tolerance in High Fat Fed Male Wistar Rats. In: *Journal of Clinical and Diagnostic Research* [online]. 2015, 9(2), 01–04 [cit. 2021-03-09]. Dostupné z: doi:10.7860/JCDR/2015/12045.5577
418. Chen, T. H. et al. The Exploration of Natural Compounds for Anti-Diabetes from Distinctive Species *Garcinia linii* with Comprehensive Review of the *Garcinia* Family. *Biomolecules*. 2019, 9(11), 641.

419. Chuah, L. O. et al. *In Vitro* and *In Vivo* Toxicity of *Garcinia* or Hydroxycitric Acid: A Review. In: *Evidence-Based Complementary and Alternative Medicine* [online]. 2012 [cit. 2021-03-18]. Dostupné z: doi:10.1155/2012/197920
420. Maia-Landim, A. et al. Long-term effects of *Garcinia cambogia*/Glucosaminan on weight loss in people with obesity, PLIN4, FTO and Trp64Arg polymorphisms. *BMC Complementary and Alternative Medicine*. 2018, 18(1), 26.
421. Yang, F. a Zheng, J. Understand spiciness: mechanism of TRPV1 channel activation by capsaicin. *Protein & Cell*. 2017, 8(3), 169–177.
422. Chung, M. K. a Campbell, J. N. Use of Capsaicin to Treat Pain: Mechanistic and Therapeutic Considerations. *Pharmaceuticals (Basel, Switzerland)*. 2016, 9(4), 66.
423. Sánchez, A. M. et al. Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicin. *Apoptosis*. 2006, 11(1), 89–99.
424. Lv, J. et al. Consumption of spicy foods and total and cause specific mortality: population based cohort study. *BMJ*. 2015, 351.
425. Smutzer, G. a Dévassy, R. K. Integrating TRPV1 Receptor Function with Capsaicin Psychophysics. *Adv Pharmacol Sci*. In: *Advances in Pharmacological and Pharmaceutical Sciences* [online]. 2016 [cit. 2020-10-09]. Dostupné z: doi:10.1155/2016/1512457
426. Kawada, T. et al. Capsaicin-induced beta-adrenergic action on energy metabolism in rats: influence of capsaicin on oxygen consumption, the respiratory quotient, and substrate utilization. *Proceedings of the Society for Experimental Biology and Medicine*. 1986, 183(2), 250–256.
427. Yoshioka, M. et al. Effects of red-pepper diet on the energy metabolism in men. *Journal of Nutritional Science and Vitaminology (Tokyo)*. 1995, 41(6), 647–656.
428. Yoshioka, M. et al. Effects of red pepper on appetite and energy intake. *British Journal of Nutrition*. 1999, 82(2), 115–123.
429. Yoshioka, M. et al. Maximum tolerable dose of red pepper decreases fat intake independently of spicy sensation in the mouth. *British Journal Of Nutrition*. 2004, 91(6), 991–995.
430. Hursel, R. a Westerterp-Plantenga, M. S. Thermogenic ingredients and body weight regulation. *International Journal of Obesity (London)*. 2010, 34(4), 659–669.
431. Whiting, S., Derbyshire, E. J. a Tiwari B. Could capsaicinoids help to support weight management? A systematic review and meta-analysis of energy intake data. *Appetite*. 2014, 73, 183–188.
432. Janssens, P. L. et al. Acute effects of capsaicin on energy expenditure and fat oxidation in negative energy balance. In: *PLoS One* [online]. 2013, 8(7) [cit. 2021-03-19]. Dostupné z: doi:10.1371/journal.pone.0067786
433. Shin, K. O. a Moritani, T. Alterations of autonomic nervous activity and energy metabolism by capsaicin ingestion during aerobic exercise in healthy men. *Journal of Nutritional Science and Vitaminology (Tokyo)*. 2007, 53(2), 124–132.
434. Lejeune, M. P., Kovacs, E. M. a Westerterp-Plantenga, M. S. Effect of capsaicin on substrate oxidation and weight maintenance after modest body-weight loss in human subjects. *British Journal of Nutrition*. 2003, 90(3), 651–659.
435. Shin, K. O., Yeo, N. H. a Kang, S. Autonomic Nervous Activity and Lipid Oxidation Postexercise with Capsaicin in the Humans. *Journal of Sports Science and Medicine*. 2010, 9(2), 253–261.
436. Ludy, M. J., Moore, G. E. a Mattes, R. D. The effects of capsaicin and capsiate on energy balance: critical review and meta-analyses of studies in humans. *Chemical Senses*. 2012, 37(2), 103–121.
437. Muzammil, M., Satish, S. a Gafoor, H. A Systematic Review on Natural Sedative and Hypnotics. *International Journal of Pharmaceutical Sciences Review and Research*. 2020, 60(1), 94–98.
438. Martin, J. a Martinová, D. Léčivé rostliny s hypnotickým a sedativním účinkem. *Praktické Lékařství*. 2014, 10(6), 226–229.
439. Cutando, A. et al. Role of melatonin in cancer treatment. *Anticancer Research*. 2012, 32(7), 2747–2753.
440. Reiter, R. J. et al. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. *International Journal of Molecular Sciences*. 2017, 18(4), 843.
441. Li, Y. et al. Melatonin for the prevention and treatment of cancer. *Oncotarget*. 2017, 8(24), 39896–39921.
442. Talib, W. H. Melatonin and Cancer Hallmarks. *Molecules (Basel, Switzerland)*. 2018, 23(3), 518.
443. Wang, Y. et al. Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis. *OncoTargets and therapy*. 2018, 11, 7895–7908.
444. Birdsall, T. C. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. *Alternative Medicine Review*. 1998, 3(4), 271–280.
445. Green, A. R. et al. Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. *British Journal of Clinical Pharmacology*. 1980, 10(6), 603–610.
446. Jennifer, H., Mariana, P. a Karyn, B. Serotonin Syndrome from 5-Hydroxytryptophan Supplement Ingestion in a 9-Month-Old Labrador Retriever. *Journal of Medical Toxicology*. 2017, 13(2), 183–186.
447. Singh, S. et al. Boswellic acids: A leukotriene inhibitor also effective through topical application in inflammatory disorders. *Phytomedicine*. 2008, 15(6–7), 400–407.
448. Kimmatkar, N. et al, Efficacy and tolerability of *Boswellia serrata* extract in treatment of osteoarthritis of knee—a randomized double blind placebo controlled trial. *Phytomedicine*. 2003, 10(1), 3–7.

449. Siddiqui, M. Z. *Boswellia serrata*, a potential antiinflammatory agent: an overview. *Indian Journal of Pharmaceutical Sciences*. 2011, 73(3), 255–261.
450. Roy, N. K. et al. An Update on Pharmacological Potential of Boswellic Acids against Chronic Diseases. *International Journal of Molecular Sciences*. 2019, 20(17), 4101.
451. Alluri, V. K. et al. An Anti-Inflammatory Composition of *Boswellia serrata* Resin Extracts Alleviates Pain and Protects Cartilage in Monoiodoacetate-Induced Osteoarthritis in Rats. In: *Evidence-Based Complementary and Alternative Medicine* [online]. 2020 [cit. 2021-01-10]. Dostupné z: doi:10.1155/2020/7381625
452. Smithson, J., Kellick, K. A. a Mergenhagen, K. *Nutritional Modulators of Pain in the Aging Population*. 1st Edition, Cambridge: Academic Press, 2017. ISBN 9780128051863.
453. Drovanti, A., Bignamini, A. A. a Rovati, L. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: A placebo-controlled double-blind investigation. *Clinical Therapeutics*. 1980, 3(4), 260–272.
454. Reginster, J. Y. et al. Evidence of nutraceutical effectiveness in the treatment of osteoarthritis. *Current Rheumatology Reports*. 2000, 2(6), 472–477.
455. Pavelká, K. et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. *Archives of internal medicine*. 2002, 162(18), 2113–2123.
456. David-Raoudi, M. et al. Chondroitin sulfate increases hyaluronan production by human synoviocytes through differential regulation of hyaluronan synthases: Role of p38 and Akt. *Arthritis & Rheumatology*. 2009, 60(3), 760–770.
457. Krane, S. M. a Goldring, M. B. Clinical implications of cartilage metabolism in arthritis. *European Journal of Rheumatology*. 1990, 10(1), 4–9.
458. Chan, P. S. et al. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E₂ in articular cartilage explants. *Osteoarthritis and Cartilage*. 2005, 13(5), 387–394.
459. Ha, B. J. Oxidative stress in ovariectomy menopause and role of chondroitin sulfate. *Archives of Pharmacol Research*. 2004, 27(8), 867–872.
460. Mazieres, B., Hucher, M. a Zaim, M. Chondroitin sulfate in the treatment for knee osteoarthritis: A randomized, double blind, multicenter, placebo-controlled trial. *Osteoarthritis Cartilage*. 2005, 13(Suppl 1), S74.
461. Evans, M. S., Reid, K. H. a Sharp J. B. Jr. Dimethylsulfoxide (DMSO) blocks conduction in peripheral nerve C fibers: a possible mechanism of analgesia. *Neuroscience Letters*. 1993, 150(2), 145–148.
462. Kalman, D. S. et al. Influence of methylsulfonylmethane on markers of exercise recovery and performance in healthy men: a pilot study. *Journal of the International Society of Sports Nutrition*. 2012, 9(1), 46.
463. Van der Merwe, M. a Bloomer R. J. The influence of methylsulfonylmethane on inflammation-associated cytokine release before and following strenuous exercise. In: *International Journal of Journal of Sports Medicine (Hindawi)* [online]. 2016 [cit. 2020-11-05]. Dostupné z: doi:10.1155/2016/7498359
464. Barmaki, S. et al. Effect of methylsulfonylmethane supplementation on exercise - Induced muscle damage and total antioxidant capacity. *The Journal of Sports Medicine and Physical Fitness*. 2012, 52(2), 170–174.
465. Barrager, E. et al. A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis. *Journal of Alternative and Complementary Medicine*. 2002, 8(2), 167–173.
466. Barrager, E. a Schauss, A. G. Methylsulfonylmethane as a treatment for seasonal allergic rhinitis: additional data on pollen counts and symptom questionnaire. *Journal of Alternative and Complementary Medicine*. Med. 2003, 9(1), 15–16.
467. Muizzuddin, N. a Benjamin, R. Beauty from within: Oral administration of a sulfur-containing supplement methylsulfonylmethane improves signs of skin ageing. *International Journal for Vitamin and Nutrition Research*. 2020, 1–10.
468. McCabe, D. et al. Polar solvents in the chemoprevention of dimethylbenzanthracene-induced rat mammary cancer. *Archives of Surgery*. 1986, 121(12), 1455–1459.
469. Horvath, K. et al. Toxicity of methylsulfonylmethane in rats. *Food and Chemical Toxicology*. 2002, 40(10), 1459–1462.
470. Caron, J. M. et al. Methyl Sulfone Induces Loss of Metastatic Properties and Reemergence of Normal Phenotypes in a Metastatic Cloudman S-91 (M3) Murine Melanoma Cell Line. In: *PLoS ONE* [online]. 2010, 5(8) [cit. 2020-08-24]. Dostupné z: doi:10.1371/journal.pone.0011788
471. Moazzami, A. A. et al. Nuclear magnetic resonance-based metabolomics enable detection of the effects of a whole grain rye and rye bran diet on the metabolic profile of plasma in prostate cancer patients. *Journal of Nutrition*. 2011, 141(12), 2126–2132.
472. Lim, E. J. et al. Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways. In: *PLoS ONE* [online]. 2012, 7(4). [cit. 2020-12-09]. Dostupné z: doi:10.1371/journal.pone.0033361
473. Nipin, S. et al. The combination of methylsulfonylmethane and tamoxifen inhibits the jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in er-positive breast cancer xenografts. *BMC Cancer*. 2015, 15, 474.
474. Butawan, M., Benjamin, R. L. a Bloomer, R. J. Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement. *Nutrients*. 2017, 9(3), 290.